Pharma Focus Asia

Itemization Difference of Patient-reported Outcome in Patients with Chronic Liver Disease

Ming-Chieh Lin, Chia-Yen Dai, Chung-Feng Huang, Ming-LunYeh, Yi-Chan Liu, Po-Yao Hsu, Yu-Ju Wei, Pei-Lun Lee, Ching-I Huang, Po-Cheng Liang, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Zu-Yau Lin, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang

Abstract
The itemization difference of patient-reported outcome (PRO) in hepatitis patients with different etiologies remains elusive in Asia. We aimed to assess the characteristics and the difference of health-related quality of life (HRQoL) in chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver disease (NAFLD) patients.

Introduction
Hepatitis is a worldwide huge health concern, largely due to its subsequent sequela such as cirrhosis, liver failure and hepatocellular carcinoma (HCC). The causes and/or etiologies vary in different regions globally. Viral hepatitis infections, mainly hepatitis B virus (HBV) and C virus (HCV), are prevalent in Asia-Pacific region.

Materials and Methods:
The ethical committee of the Kaohsiung Medical University Hospital approved this study before it was performed (KMUHIRB-E1-20170279). This prospective cohort study was conducted at a medical center hospital, three regional hospitals, and a primary care center in southern Taiwan. During the period from January 2008 to August 2018. Those treatment-naïve patients who have been diagnosed of CHB, CHC or NAFLD for more than 6 months were consecutively enrolled.

Discussion
HRQoL remains a major concern of general health. A comprehensive understanding of HRQoL among CLD patients would give insight to physical and mental challenges the patients may face.The current study demonstrated the significant difference of HRQoL existed between CLD of different etiologies. Our itemization results showed that CHC patients had a lower PCS score, particularly in the items of BP and PF.

Acknowledgments: The authors thank secretary help from Taiwan Liver Research Foundation (TLRF). The foundation did not influence how the study was conducted or the approval of the manuscript.

Citation: Lin M-C, Dai C-Y, Huang C-F, Yeh M-L, Liu Y-C, Hsu P-Y, et al. (2022) Itemization difference of patient-reported outcome in patients with chronic liver disease. PLoS ONE 17(2): e0264348. https://doi.org/10.1371/journal.pone.0264348

Editor: EvyYunihastuti, Universitas Indonesia FakultasKedokteran, INDONESIA

Received: July 23, 2021; Accepted: February 8, 2022; Published: February 22, 2022.

Copyright: © 2022 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript.

Funding: This study was supported partly by grant from Kaohsiung Medical University (grant number 97CM-KMU for the author Jee-Fu Huang) and Kaohsiung Medical University Hospital (grant number SA10907 for the author Jee-Fu Huang). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024